Relevant bibliographies by topics / Zyflamend

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Conference papers

Academic literature on the topic 'Zyflamend'

Author: Grafiati
Published: 4 June 2021
Last updated: 4 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Zyflamend.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Zyflamend"

1

Puckett, Dexter, Mohammed Alquraishi, Samah Chahed, Dina Alani, Victoria Frankel, Brynn Voy, Dallas Donohoe, Jay Whelan, and Ahmed Bettaieb. "Zyflamend, a Unique Herbal Blend, Inhibits Adipogenesis Through the Coordinated Regulation of PKA and JNK." Current Developments in Nutrition 4, Supplement_2 (May 29, 2020): 454. http://dx.doi.org/10.1093/cdn/nzaa045_087.

Full text
Abstract:
Abstract Objectives The prevalence of obesity and its comorbidities has sparked a worldwide concern to address rates of adipose tissue accrual. Recent studies have demonstrated a novel role of Zyflamend, a natural herbal extract, in regulating lipid metabolism in several cancer cell lines through the activation of the AMPK signaling pathway. Yet, the role of Zyflamend in adipogenic differentiation and lipid metabolism remains largely unexplored. The objective of this study is to investigate the effects of Zyflamend on white 3T3-MBX pre-adipocyte differentiation and elucidate the molecular mechanisms. Methods 3T3-MBX pre-adipocytes were treated with Zyflamend, and the expression of various key adipogenic and lipolytic regulators was examined. We also investigated the effects of Zyflamend on pre-adipocyte survival, proliferation, and cell cycle. Results Zyflamend treatment altered cell cycle progression, attenuated proliferation, and increased cell death of 3T3-MBX pre-adipocytes. In addition, treatment with Zyflamend inhibited lipid accumulation during the differentiation of 3T3-MBX cells, consistent with decreased expression of lipogenic genes and increased lipolysis. Mechanistically, Zyflamend-induced alterations in adipogenesis were mediated, at least in part, through the activation of AMPK, PKA, and JNK. Inhibition of AMPK partially reversed Zyflamend-induced inhibition of differentiation, whereas the inhibition of either JNK or PKA fully restored adipocyte differentiation and decreased lipolysis. Conclusions Taken together, the present study demonstrates that Zyflamend, as a novel anti-adipogenic bioactive mix, inhibits adipocyte differentiation through the activation of PKA and JNK pathways.Our findings suggest that Zyflamend supplementation might help in developing novel anti-obesity therapeutic strategies. Funding Sources This work was supported by the National Institute of Diabetes and Digestive and Kidney Diseases (R00DK100736) to A.B.
APA, Harvard, Vancouver, ISO, and other styles
2

Bilen, Mehmet Asim, Sue-Hwa Lin, Dean G. Tang, Kinjal Parikh, Mong-Hong Lee, Sai-Ching J. Yeung, and Shi-Ming Tu. "Maintenance Therapy Containing Metformin and/or Zyflamend for Advanced Prostate Cancer: A Case Series." Case Reports in Oncological Medicine 2015 (2015): 1–5. http://dx.doi.org/10.1155/2015/471861.

Full text
Abstract:
Metformin is derived from galegine, a natural ingredient, and recent studies have suggested that metformin could enhance the antitumor effects of hormone ablative therapy or chemotherapy and reduce prostate cancer-specific mortality. Zyflamend is a combination of herbal extracts that reduces inflammation and comprises turmeric, holy basil, green tea, oregano, ginger, rosemary, Chinese goldthread, hu zhang, barberry, and basil skullcap. We propose a maintenance regimen with metformin and/or Zyflamend that targets cancer stem cells and the tumor microenvironment to keep the cancer dormant and prevent it from activation from dormancy. Herein, we report the clinical course of four patients who experienced a clinical response after treatment with metformin and/or Zyflamend.
APA, Harvard, Vancouver, ISO, and other styles
3

Ekmekcioglu, Suhendan, Chandrani Chattopadhyay*, Ugur Akar*, Abdul Gabisi, Robert A. Newman, and Elizabeth A. Grimm. "Zyflamend Mediates Therapeutic Induction of Autophagy to Apoptosis in Melanoma Cells." Nutrition and Cancer 63, no. 6 (August 2011): 940–49. http://dx.doi.org/10.1080/01635581.2011.586488.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Tague, Eric D., Allen K. Bourdon, Amber MacDonald, Maggie S. Lookadoo, Edward D. Kim, Wesley M. White, Paul D. Terry, Shawn R. Campagna, Brynn H. Voy, and Jay Whelan. "Metabolomics Approach in the Study of the Well-Defined Polyherbal Preparation Zyflamend." Journal of Medicinal Food 21, no. 3 (March 2018): 306–16. http://dx.doi.org/10.1089/jmf.2017.0062.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Hume, Anne L. "Zyflamend for prevention of prostate cancer: Studies show benefits, but larger trials needed." Pharmacy Today 20, no. 7 (July 2014): 30. http://dx.doi.org/10.1016/s1042-0991(15)30779-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Puckett, Dexter L., Mohammed Alquraishi, Samah L. Chahed, Dallas R. Donohoe, Jay Whelan, and AHMED BAETTAIEB. "Zyflamend Induces Apoptosis in Pancreatic Cancer cells via Modulation of the JNK Pathway." FASEB Journal 34, S1 (April 2020): 1. http://dx.doi.org/10.1096/fasebj.2020.34.s1.09714.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Zhao, Yi, Dallas Donohoe, E.-Chu Huang, and Jay Whelan. "Zyflamend, a polyherbal mixture, inhibits lipogenesis and mTORC1 signalling via activation of AMPK." Journal of Functional Foods 18 (October 2015): 147–58. http://dx.doi.org/10.1016/j.jff.2015.06.051.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Katz, A. E., P. M. Pierorazio, P. Masson, E. T. Goluboff, B. A. Stone, J. M. McKiernan, M. C. Benson, and C. A. Olsson. "Results of a phase I trial administering Zyflamend to subjects with high-grade prostatic intraepithelial neoplasia." Journal of Clinical Oncology 24, no. 18_suppl (June 20, 2006): 14575. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.14575.

Full text
Abstract:
14575 Background: Subjects diagnosed with prostatic intraepithelial neoplasia (PIN) at prostate biopsy are at increased risk of developing prostate cancer on later biopsies. We initiated a phase I clinical trial to asses the safety and efficacy of the novel herbal anti-inflammatory, Zyflamend, to prevent prostate cancer in high-risk subjects with PIN. Methods: Men ages 40–75 diagnosed with high-grade PIN (without prostate cancer) on biopsy within the last six months were enrolled. Patients were assigned to one of eight treatment groups, with successive dose-escalation occurring in each group. Patients were evaluated every three months for 18 months; at which time they had a physical exam and blood samples drawn to monitor for toxicity, to check for fluctuations in PSA and testosterone, and monitor a battery of inflammatory serum. At 6, 12 and 18 months, 12-core transrectal ultrasound guided biopsy of the prostate was performed. Biopsy tissue was evaluated for the presence of PIN and/or prostate cancer then stained for inflammatory biomarkers. A NCI common terminology criteria for adverse events (v3.0) based questionnaire was used to monitor side effects. Endpoints are completion of the 18 month protocol without adenocarcinoma or diagnosis of adenocarcinoma prior to 18 months. Results: To date 25 patients have been enrolled; the expected closure date is March, 2006. The median patient age is 65.1 years with a median PSA level of 6.8. There have been no adverse events reported or toxicities apparent. Five patients (20%) have complained of grade I dyspepsia resolving spontaneously without intervention. Preliminary results include a total of 22 biopsies performed in 19 patients. 18 of the 22 biopsies were performed per protocol at scheduled visits, the remaining four were performed between scheduled visits. Of 22 biopsies completed seven returned positive for PIN (31.8%) and three have returned with adenocarcinoma (13.6%). Conclusions: The novel herbal anti-inflammatory, Zyflamend, appears to be associated with minimal toxicity and no serious adverse events when administered orally. Short term biopsy results indicate a low progression rate, although long-term efficacy awaits further studies. No significant financial relationships to disclose.
APA, Harvard, Vancouver, ISO, and other styles
9

Huang, E.-Chu, Guoxun Chen, Seung Joon Baek, Michael F. McEntee, J. Jason Collier, Steven Minkin, John Biggerstaff, and Jay Whelan. "Zyflamend Reduces the Expression of Androgen Receptor in a Model of Castrate-Resistant Prostate Cancer." Nutrition and Cancer 63, no. 8 (November 2011): 1287–96. http://dx.doi.org/10.1080/01635581.2011.606956.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Huang, E. Chu, Michael F. McEntee, and Jay Whelan. "Zyflamend, a Combination of Herbal Extracts, Attenuates Tumor Growth in Murine Xenograft Models of Prostate Cancer." Nutrition and Cancer 64, no. 5 (July 2012): 749–60. http://dx.doi.org/10.1080/01635581.2012.689413.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Zyflamend"

1

Huang, E.-Chu. "Mechanisms Associated with the Chemotherapeutic Effects of Zyflamend, a Multi-Herbal Extract, on Advanced Prostate Cancer." 2010. http://trace.tennessee.edu/utk_graddiss/888.

Full text
Abstract:
Advanced prostate cancer (PrC) is the second leading cause of death from cancer in US males. Advanced PrC cells are initially androgen-sensitive and thus androgen ablation therapy causes tumors to undergo regression and fall into a remission phase where residual cells remain dormant while androgen levels remain very low. Unfortunately, this phase usually lasts 3 to 5 years prior to tumor relapse, where the tumor cells re-grow in the absence of androgens. This form of the disease is aggressive and invariably fatal. In this study, we investigated the effects of a combination of herbal extracts on various stages of PrC, androgen-dependent and castrate-resistant, using CWR22 and CWR22Rv1 cells, respectively. Zyflamend, a commercially available product consisting of 10 different herbal extracts, had been shown to reduce pre-malignant forms of PrC in clinical trials. We expanded these earlier experiments by using Zyflamend in a model of advanced PrC. Our initial results indicated that Zyflamend could repress androgen-sensitive and castrate-resistant (androgen-insensitive) prostate tumor growth. Using a cell model for castrate-resistant PrC, Zyflamend inhibited the growth of CWR22Rv1 cells by increasing the expression of the cell cycle inhibitors p21 and p27. These effects were mediated via hyperacetylation of histone 3 through the suppression of class I and II histone deacetylases (HDACs) and an induction of CBP/p300 histone acetyl transferase activity. The latter effect was mediated by the upregulation/activation of Erk-1/-2 and Elk-1. Zyflamend also inhibited androgen receptor expression, its downstream gene target, prostate specific antigen (PSA), and increased cell death by inducing apoptosis as indicated by caspase 3 activity and PARP cleavage. The reduction of androgen receptor was confirmed in CWR22Rv1 xenograft tissues. Our results suggest the extracts of this herbal combination inhibits castrate-resistant prostate cancer cell growth epigenetically and by coordinately affecting androgen receptor signaling pathways involved in cell growth/death. In an androgen-dependent PrC tumor xenograft model, Zyflamend reduced the growth of CWR22-derived tumors and enhanced the responsiveness of tumor cells to hormone ablation. Zyflamend potentiated the regression of PrC cells and their sensitivity to androgen deprivation. These results suggest that Zyflamend may be an effective adjuvant when used with hormone ablation therapy.
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Zyflamend"

1

Gutierrez-Barrera, Angelica M., Banu K. Arun, Peiying Yang, and Carrie Cartwright. "Abstract 3218: Zyflamend, a multi-herbal product, selectively inhibits the growth of triple negative breast cancer cellsin vitro." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-3218.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Yan, Jun, Cory Abate‐Shen, and Aaron E. Katz. "Abstract B75: Herbal extract amalgam Zyflamend suppresses prostate cancer cell growth and survival through inducing androgen receptor degradation and inhibiting AR signaling." In Abstracts: AACR International Conference on Frontiers in Cancer Prevention Research‐‐ Dec 6–9, 2009; Houston, TX. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1940-6207.prev-09-b75.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Zyflamend' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography